The TPP Is Dead. Long Live Free Trade.
Executive Summary
With the Trans-Pacific Partnership multinational trade deal seemingly dead in the water, attention is now turning to potential alternative trade agreements in the Asia-Pacific region. But how might these play out for the global pharma industry?
You may also be interested in...
Why Now Is The Right Time For Mutual Recognition
20 years later, signs that this time the US EU mutual recognition agreement won’t fizzle.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.